Compare DRD & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | COAG |
|---|---|---|
| Founded | 1895 | 2020 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2002 | 2026 |
| Metric | DRD | COAG |
|---|---|---|
| Price | $22.93 | $38.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.00 |
| AVG Volume (30 Days) | 226.0K | ★ 476.4K |
| Earning Date | 02-12-2027 | 11-10-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $18.47 | N/A |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.47 | $27.38 |
| 52 Week High | $39.37 | $55.42 |
| Indicator | DRD | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 53.48 |
| Support Level | $22.76 | $28.46 |
| Resistance Level | $26.57 | $51.07 |
| Average True Range (ATR) | 0.77 | 3.72 |
| MACD | -0.11 | -0.20 |
| Stochastic Oscillator | 13.41 | 37.45 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment, including exploration, extraction, processing, and smelting. Its reportable operating segments are: Ergo and FWGR. Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and FWGR is a surface gold retreatment operation that treats old slime dams in the West Rand goldfields. The Ergo segment derives the vast majority of the company's revenue.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.